New onset severe ulcerative colitis following Ixekizumab therapy
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease.
##plugins.themes.bootstrap3.article.details##
Ixekizumab, psoriasis, ulcerative colitis, toxic megacolon, colectomy
2. Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O'Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020; 9:2020-2-1. doi: 10.7573/dic.2020-2-1.
3. Raychaudhuri, S.K., Raychaudhuri, S.P. IL-17 and Its Receptor System: a New Target for Psoriatic Arthritis. Curr Treat Options in Rheum. 2015; 1:210-220. doi.org/10.1007/s40674-015-0019-2.
4. Vlachos C, Gaitanis G, Katsanos KH, et al. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis. 2016; 6(1):73-92. doi: 10.2147/PTT.S85194.
5. Gálvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014; 2014:1-14. doi: 10.1155/2014/928461.
6. Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, Secukinumab, ixekizumab, and others. Curr Probl Dermatol. 2018; 53:49-63. doi: 10.1159/000479475.
7. Fauny M, Moulin D, D'Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020; 79(9):1132-1138. doi: 10.1136/annrheumdis-2020-217927.
8. Whibley N, Gaffen SL. Gut-Busters: IL-17 Aint Afraid of No IL-23. Immunity. 2015; 43:620-622. doi: 10.1016/j.immuni.2015.10.001.
9. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-1700. doi: 10.1136/gutjnl-2011-301668.
10. Nehring P, Przybyłkowsk A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?. Pharmaceutical Medicine. 2020; 34(1):257-262. doi: 10.1007/s40290-020-00340-1.
11. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016; 175(3):487-492. doi: 10.1111/bjd.14528.
12. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018; 29(1):13-18. doi: 10.1080/09546634.2017.1329511.
13. Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020; 59(12):3834-3844. doi: 10.1093/rheumatology/keaa189.
14. Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV. Severe de novo Ulcerative Colitis following Ixekizumab Therapy. Case Rep Gastroenterol. 2018; 12(3):617-621. doi: 10.1159/000493922.
15. Mu X, Fardy J, Reid S, Trahey J. Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis. BMC Gastroenterol. 2021; 21(1):361. doi: 10.1186/s12876-021-01936-w.
16. Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019; 50(4):373-385. doi: 10.1111/apt.15397.
17. Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017; 76(3):441-448. doi: 10.1016/j.jaad.2016.10.027.
18. Burisch J, Eigner W, Schreiber S, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0233781. doi: 10.1371/journal.pone.0233781.
19. Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017; 76(3):432-440. doi: 10.1016/j.jaad.2016.09.026.
20. Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatol Ther. 2022; 12(6):1431-1446. doi: 10.1007/s13555-022-00743-9.
21. Penso L, Bergqvist C, Meyer A, et al. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System. Arthritis Rheumatol. 2022; 74(2):244-252. doi: 10.1002/art.41923.
22. Wright S, Alloo A, Strunk A, Garg A. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors. J Am Acad Dermatol. 2020; 83(2):382-387. doi: 10.1016/j.jaad.2020.04.010.
23. Fauny M, D'Amico F, Bonovas S, et al. Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. J Crohns Colitis. 2020; 14(5):688-693. doi: 10.1093/ecco-jcc/jjz205.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.